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Abstract: Neuroinflammation is an essential part of neurodegeneration. Yet, the current under-
standing of neuroinflammation-associated molecular events in distinct brain regions of prion dis-
ease patients is insufficient to lay the ground for effective treatment strategies targeting this com-
plex neuropathological process. To address this problem, we analyzed the expression of 800
neuroinflammation-associated genes to create a profile of biological processes taking place in the
frontal cortex and cerebellum of patients who suffered from sporadic Creutzfeldt–Jakob disease. The
analysis was performed using NanoString nCounter technology with human neuroinflammation
panel+. The observed gene expression patterns were regionally and sub-regionally distinct, sug-
gesting a variable neuroinflammatory response. Interestingly, the observed differences could not be
explained by the molecular subtypes of sporadic Creutzfeldt–Jakob disease. Furthermore, analyses
of canonical pathways and upstream regulators based on differentially expressed genes indicated
an overlap between biological processes taking place in different brain regions. This suggests that
even smaller-scale spatial data reflecting subtle changes in brain cells’ functional heterogeneity and
their immediate pathologic microenvironments are needed to explain the observed differential gene
expression in a greater detail.
Keywords: prion disease; Creutzfeldt–Jakob disease; neuroinflammation; microglia; immune re-
sponse; gene expression analysis; brain microenvironment; regional pathogenesis; biomarkers
1. Introduction
Prion diseases, which are caused by misfolded cellular prion proteins termed pri-
ons and denoted PrPSc, are a group of infectious and invariably fatal neurodegenerative
diseases that can be acquired (<1%), genetic (∼15%), and sporadic (85%) [1–4]. Spo-
radic Creutzfeldt–Jakob disease (sCJD), the most common of all PrPSc prion diseases, has
14 subtypes that are defined by the methionine/valine polymorphism at codon 129 in
the prion protein gene (PRNP), a type of present protease K-resistant PrPSc fragments
(type 1 = 21 kDa, type 2 = 19 kDa), and distinct phenotypic features such as the appearance
and distribution of Kuru plaques and pronounced cortical or thalamic changes [5–9].
The templated misfolding of cellular prion protein (PrPC) into PrPSc is central to the
disease pathogenesis [10]. However, neurodegeneration is a result of multiple complex
molecular processes occurring in different brain regions simultaneously. In sCJD, a highly
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variable selective regional vulnerability, although poorly understood, can be observed in
different disease subtypes [11–13].
It has become clear that several brain region-specific factors must play a role. Specific
cell types, with their intrinsic firing properties and metabolic activity, varying concen-
trations of metal ions, and differences in toxicity restricting molecular machines such
as protein-folding and quality-control systems, are considered to be involved in region
selection for the establishment of neurodegeneration [12].
As has been shown by many studies of prion disease animal models, neuroinflam-
mation is an inseparable part of neurodegeneration [14–16]. Several studies investigating
gene expression in various prion disease models indicate that upregulated genes are pre-
dominantly expressed by activated microglia, suggesting their major role in the regulation
of inflammation, metabolism, respiratory stress, and possibly other functions [17–19].
Microglia are brain-resident macrophages constantly surveilling their microenviron-
ment to ensure the elimination of brain cell function-disturbing events [20]. Upon the
detection of abnormal activity, depending on the stimuli, microglia initiate different re-
sponses to stabilize the microenvironment [21].
Accumulating evidence suggests that microglia also play a role in synaptic organiza-
tion, the control of neuronal excitability, phagocytic debris removal, trophic support for
brain protection and repair, the induction of neurotoxic reactive astrocyteskilling neurons
and mature oligodendrocytes [19,22,23].
However, surprisingly little is known about regional microglia-induced neuroinflam-
mation patterns even in the most common human prion diseases [24–26]. Understanding
the differences in potentially pathogenic molecular events taking place in different brain
regions is essential for the further deciphering of complex molecular networks, their
interactions, and their potential use for novel therapeutic strategies.
Thus, the current study was designed to provide a comprehensive overview of the
regional neuroinflammatory differences in sCJD brain samples from deceased patients
using an RNA amplification-free approach that allowed direct counting of present in the
sample RNAs of interest. RNA amplification-free solution was provided by NanoString
technologies, which also offered a 770-gene panel designed to represent the core pro-
cesses of neuroinflammation—namely, immunity and inflammation, neurobiology and
neuropathology, and metabolism and stress [27].
2. Results
2.1. Regional Differences in Gene Expression
Based on the 265 most variably expressed genes across all the samples included in the
study (Supplementary material S1a, a list of the 265 genes), the following main patterns
were observed: (1) primary separation between the frontal cortex (FC) and cerebellum (CB)
samples, and (2) secondary separation of sCJD from control tissue samples (Figure 1a,b).
The gene expression signature of sCJD CB sample FFCJD_CB-20 suggested that it was
an FC sample, and thus it was removed from further analyses. Due to major differences
in gene expression profiles between FC and CB, as illustrated in the heatmap (Figure 1a),
these tissues were treated separately in the subsequent analyses.
2.2. Top Differentially Expressed Genes (DEGs)
The neuroinflammatory gene analysis revealed several significantly differentially
expressed and functionally interesting genes. We were most interested in identifying
Differentially Expressed Genes (DEGs) that would be (1) common to both brain regions in
sCJD samples as compared to controls; (2) unique to each brain region in sCJD samples as
compared to controls; and (3) unique to a brain region regardless of sample type—i.e., sCJD
or control. The three groups of DEGs identified following these comparison criteria were
named as follows: (1) disease-specific, brain region non-exclusive DEGs; (2) disease-specific,
brain region exclusive DEGs; and (3) disease non-specific, brain region exclusive DEGs.
Table 1 provides an overview of the top genes that belong to each group of interest.
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Apoptosis; cellular response to 
echanical stimulus; leukocyte 
igration; response to endoplas-
mic reticulum stress. 
Cere-
bellum 




G-protein coupled receptor; 
transducer; protein heterodimeri-
zation activity; protein homodi-
merization activity. 
Cellular response to hormone 
stimulus; glucose homeostasis; 
positive regulation of cell migra-
tion, cell population proliferation, 





Receptor 2  
G-protein coupled receptor; 
transducer; may mediate sup-
pression of neurotransmission or 
may be involved in synaptogene-
sis or synaptic stabilization. 
Chemical synaptic transmission; 
glutamate homeostasis and secre-
tion; G protein-coupled glutamate 
receptor signaling pathway; regu-
lation of synaptic transmission, 
glutamatergic. 




Hydrolase; in neurons, involved 
in the inhibition of the initial 
spine growth. Upon activation by 
CaMKII, modulates dendritic 
spine structural plasticity. 
Cell cycle; cell division; host-virus 
interaction; cerebral cortex cell mi-
gration; cellular response to chem-
okine and cytokine stimuli; fore-
brain radial glial cell differentia-
tion; neuron apoptosis, morpho-































Adapter protein; cargo receptor 
activi y; clathr  adaptor activity; 
protei  r inus binding; 
SMAD binding. 
Apoptotic process; cell differentia-
tion; membrane organization; pro
i  transport; negative regulation 
of protein bindin  and protein l -
calizatio to plasm  membra e; 
positive regulation of cell migra-






A receptor for fibronectin; integ-
rin binding; signali g receptor 
activ ty; v rus receptor a tivity. 
Cell adhesion mediated by integ-
rin; cell migration; extracellular 
matrix organization; stress fiber 
assembly; host-v rus interaction. 







Coupl  i ls from receptor 
and cytoplasmic tyrosine kinases 
to the Ras signaling pathway. 
Cell-cell signaling; Ras protein sig-
na  transductio ; sensory p rcep-
i n of s und. 
TGFBR1,  
Transforming 
G owth Factor 
Beta Receptor 1  
Serine/threonine-protein kinase; 
r ceptor; activin binding; ATP 
binding; metal ion binding; 
SMAD binding; transforming 
growth factor be a binding. 
Apoptosis; differentiation; growth 
regulation.




Member 10b  
Receptor for the cytotoxic ligand 
TNFSF10/TRAIL mediating 
apoptosis; promotes the activa-
tion of NF-kappa-B; essential for 
ER stress-induced apoptos s. 
Apoptosis; cellular response to 
mechanical stimulus; leukocyte 
igration; response to endoplas-
c reticulum stress. 
Cere-
bellum 




G-protein coupled receptor; 
transducer; prot in heter dimeri-
zation a tivity; protein h modi-
merization activity. 
Cellular response to hormone 
stim lus; gluco homeostasis; 
positive reg lation f cell migra-
ti n, cell population pro iferation, 





Recep or 2  
G-protein coupled receptor; 
transducer; may mediate sup-
pres ion of neurotransmi sion or 
may be involved in synaptogene-
sis or sy aptic stabilization. 
Chemical synaptic transmission; 
glutamate homeostasis and secre-
tion; G protein-c upled glutamate 
receptor signaling athway; regu-






Hydrolase; in neurons, involved 
in the inhib tion of the initia  
spin  growth. Upon activation by 
CaMKII, modulates dendritic 
spine structura  plasticity. 
Cell cycle; cell division; host-virus 
interaction; cerebral cortex cell mi-
gration; cellular respons  to chem
okine and cytokine stimuli; for -
brain radial glial c ll differentia
tion; neuron apoptosis, morpho
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Adapter protein; cargo receptor 
activity; clathrin adaptor activity; 
protein C-terminus binding; 
SMAD binding. 
Apoptotic p ocess; cell differentia-
tion; m m rane organization; pro-
t in transp rt; negativ  regulation 
of prot in binding and protein lo-
caliz tion to plasma membran ; 
positive r gulation of cell migra-
tio nd early en osome to late 
e dosome t nsport. 




A receptor for fibronectin; in eg-
rin binding; signaling receptor 
activity; virus receptor activity. 
Cell adhesion mediated by int g-
rin; cell migra ion; extracellular 
ma rix organization; stress fiber 
assemb y; host-virus interact on. 
GRAP *,  






Couples ignals from receptor 
and cytoplasmic tyrosine kinases 
to the Ras signaling pathway. 
Cell-cell signaling; Ras protein sig-
nal transduction; sensory percep-




Beta ecept r 1  
Serine/threonine-protein kinase; 
recept ; activin bi ding; ATP 
binding; metal ion ;
SMAD binding; transforming 
growth factor beta binding.
Apoptosis; differentiation; growth 
regulation. 
TNFRSF10B *,  
Tumor Necrosis 
Factor R ceptor 
Superfamily, 
Member 10b  
Receptor for the cyto oxic ligand 
TNFSF10/TRAIL mediating 
apopto is; promotes the activa-
tion of NF-kappa-B; essential for 
ER stress-induce  apoptosis. 
Apop osis; cellular response to 
echanical stimulus; leukocyte 
migration; response to endoplas-
mic reticulum stress. 
Cere-
bellum 




G-protein coupled r ceptor; 
transducer; protein heterodimeri-
zation activity; protein homodi-
merizat on activity. 
Cellular sponse to hormone 
stimulus; glucose homeostasis; 
positive regulation of cell migra-
t o , cell pop lation proliferation, 
cytokine production; Rho protein 




Receptor 2  
G-protein coupled receptor; 
tr nsducer; may mediate sup-
pression of neurotransmission or 
may be involved in synaptogene-
sis or synaptic stabilization. 
Chemical synaptic transmission; 
glutamate homeostasis and secre
tion; G protein-coupled glutamate 
receptor si naling pathway; regu-






Hydrolase; in neurons, nvolved 
in the inhibition of th  init al 
growth. U on a tivation by 
CaMKII, modulates dendritic 
spine structural plasticity. 
Cell cycle; cell divisi ; host-virus 
interaction; cerebral cortex cell mi-
g tion; cel ular response to chem-
okine and cytokine timuli; fore
brain radial glial cell differentia-
tion; neuron apoptosis, morpho-













cell migratio , cell

























Adapter protein; cargo receptor 
activity; clathrin adaptor activity; 
protein C-terminus binding; 
SMAD bindin . 
Apoptotic process; cell differentia-
tion; membrane organization; pro-
tein transport; negative regulation 
of protein binding and protein lo-
calization to plasma membrane; 
positive regulation of cell migra-
tion and early endosome to late 
endosome transport. 
ITGB5,  
Integrin Sub it 
Beta 5 
 
A receptor for fibronectin; integ-
rin binding; signaling receptor 
activity; virus receptor activity. 
Cell adhesion mediated by integ-
rin; cel  mi r t on; extracellular 
matrix organization; tress fib r 
assembly; host-virus interaction. 




lated Adap  
Prot in 
 
Couples signals from receptor 
and cytoplasmic tyrosine kinases 
to the Ras signali g pathway. 
Cell-cell signaling; Ras protein sig-
nal transduction; sensory percep-




Beta Receptor 1  
Serine/threo ine-protein kinase; 
receptor; activin binding; ATP 
binding; metal ion binding; 
SMAD binding; transforming 
growth factor beta binding. 
Apoptosis; differentiation; growth 
regulation. 




Member 10b  
Receptor for th  cytotoxic ligand 
TNFSF10/TRAIL mediating 
apoptosis; promotes the activa-
tion of NF-kappa-B; essential for 
ER stress-induced apoptosis. 
Apoptosis; cellular response to 
echanical stimulus; l ukocyte 
migration; response to ndoplas-
mic reticulum stress. 
Cere-
bellum 




G-protein coupled receptor; 
transducer; prot in heter dimeri-
z tion a tivity; protein hom di-
m rization activity. 
Cellular response to hormone 
stimulus; glucose homeostasis; 
positive regulation of cell migra-
tion, cell population proliferation, 





Receptor 2  
G-protein coupled receptor; 
transducer; may mediate sup-
pression of neurotransmission or 
may be involved in synaptogene-
sis or synaptic stabilization. 
Chemical synaptic transmission; 
glutamate homeostasis and secre-
tion; G protein-coupled glutamate 
receptor signaling pathway; regu-






Hydrolase; in neurons, involved 
in the inhibition of the initial 
spine growth. Upon activation by 
CaMKII, modulates dendritic 
spine structural plasticity. 
Cell cycle; cell division; host-virus 
interaction; cerebral cortex cell mi-
gration; cellular response to chem-
okine and cytokine stimuli; fore-
brain radial glial cell differentia-
tion; neuron apoptosis, morpho-






neu otransm ssion or
may lved in
synaptogenesis or








regulation of sy apti
r nsmission,
glutamatergic.
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Adapter protein; cargo receptor 
activity; clathrin adaptor activity; 
protein C-terminus binding; 
SMAD binding. 
Apoptotic process; cell differentia-
tion; membrane organization; pro-
tein transport; negative regulation 
of protein binding and protein lo-
calization to plasma membrane; 
positive regulation of cell migra-






A receptor for fibronectin; integ-
rin binding; signaling receptor 
activity; virus receptor activity. 
Cell adhesion mediated by integ-
rin; cell migration; extracellular 
matrix organization; stress fiber 
assembly; host-virus interaction. 







Couples signals from receptor 
and cytoplasmic tyrosine kinases 
to the Ras signaling pathway. 
Cell-cell signaling; Ras protein sig-
nal transduction; sensory percep-




Beta Receptor 1  
Serine/threonine-protein kinase; 
receptor; activin binding; ATP 
binding; metal ion binding; 
SMAD binding; transforming 
growth factor beta binding. 
Apoptosis; differentiation; growth 
regulation. 




Member 10b  
Receptor for the cytotoxic ligand 
TNFSF10/TRAIL mediating 
apoptosis; promotes the activa-
tion of NF-kappa-B; essential for 
ER stress-induced apoptosis. 
Apoptosis; cellular response to 
mechanical stimulus; leukocyte 
migration; response to endoplas-
mic reticulum stress. 
Cere-
bellum 




G-protein coupled receptor; 
transducer; protein heterodimeri-
zation activity; protein homodi-
merization activity. 
Cellular response to hormone 
stimulus; glucose homeostasis; 
positive regulation of cell migra-
tion, cell population proliferation, 





Receptor 2  
G-protein coupled receptor; 
transducer; may mediate sup-
pression of neurotransmission or 
may be involved in synaptogene-
sis or synaptic stabilization. 
Chemical synaptic transmission; 
glutamate homeostasis and secre-
tion; G protein-coupled glutamate 
receptor signaling pathway; regu-






Hydrolase; in neurons, involved 
in the inhibition of the initial 
spine growth. Upon activation by 
CaMKII, modulates dendritic 
spine structural plasticity. 
Cell cycle; cell division; host-virus 
interaction; cerebral cortex cell mi-
gration; cellular response to chem-
okine and cytokine stimuli; fore-
brain radial glial cell differentia-
tion; neuron apoptosis, morpho-










































binding; identical protein bind-
ing; protein homodimerization 
activity; tau protein binding. 
Astrocyte differentiation; central 
nervous system development; in-
nate immune response; regulation 
of cell shape; positive regulation of 





ber 1  
Terminates the action of GABA 
by its high affinity sodium-de-
pendent reuptake into presynap-
tic terminals; identical protein 
binding; metal ion binding; neu-
rotransmitter binding. 
Neurotransmitter transport; neu-
rotransmitter reuptake; synapse 














and SOCS Box 
Containing 2  
Mediates the ubiquitination and 
subsequent proteasomal degra-
dation of target proteins. 





Homeobox 1  
Transcriptional activator or re-
pressor; plays a role in differenti-
ation of interneurons, in the de-
velopment of the ventral fore-
brain and diencephalic subdivi-
sions, in craniofacial patterning 
and morphogenesis. 






Acts as a messenger during syn-
aptic development and remodel-
ing; calmodulin binding; phos-
phatidic acid binding; phosphati-
dylinositol-3,4,5-trisphosphate 
binding. 
Nervous system development; 
positive regulation of long-term 
synaptic potentiation; postsynap-
tic modulation of chemical synap-
tic transmission; signal transduc-






Transcriptional activator; plays a 
role in brain development being 
required for the specification and 
the proliferation of the interme-
diate progenitor cells and their 
progeny in the cerebral cortex. 
Adaptive immune response; brain 
development; cell fate specifica-
tion; cerebral cortex neuron differ-
entiation; cerebral cortex regionali-






Probably transports thyroxine 
from the bloodstream to the 
brain; hormone activity; identical 
protein binding; protein-contain-
ing complex binding; thyroid 
hormone binding. 
Cellular protein metabolic process; 
extracellular matrix organization; 
neutrophil degranulation; purine 
nucleobase metabolic process. 
1 Disease-specific, brain region non-exclusive differentially expressed genes (DEGs). 2 Disease-specific, brain region exclu-
sive DEGs. 3 Disease non-specific, brain region exclusive DEGs. 4 Information gathered from http://uniprot.org. * Gene, the 
expression of which is highly differential also between the sub-clusters of the given sCJD brain region. † Gene, the expres-
sion of which is highly differential also between the sub-clusters of the sCJD cerebellum, but not frontal cortex samples. 
2.3. Inter-Regionally Overlapping Canonical Pathways and Upstream Regulators 
Within the FC samples, 184 genes were identified as differentially expressed between 
the sCJD and control tissues (Supplementary material S1b, a list of the 184 DEGs); 




























Family 6 Member 1

















binding; identical protein bind-
ing; protein homodimerization 
activity; au protein binding. 
Astrocyte differentiation; central 
nervous system de elopment; i -
nate immune resp nse; regul tion 
of cell sha e; positive regulation of 
cell population proliferation and 
apoptotic process. 
SLC A1,  
Solute Carrier 
Family 6 Mem-
ber 1  
T rmi ates the action of GABA 
by its high affinity sodium-de-
pendent reuptake into presynap-
tic terminals; identical protein 
binding; metal ion binding; neu-
rotransmitter binding. 
Neurotransmitter transpo t; neu-
rotransmitter reuptake; synapse 














and SOCS Box 
Containing 2  
Mediates he ubiquitination and 
subsequent proteasomal degra-
dation of target proteins. 





Homeobox 1  
Tra scriptional activator or re-
pressor; plays a rol  in di ferenti-
atio  of inter eurons, in the de-
velopment of the ventral fore-
brain and diencephalic subdivi-
sions, in craniofacial patterning 
nd morph genesis. 






Acts s a messenger during syn-
aptic evelopment and remodel-
ing; calm dulin binding; os-
phatidic acid binding; phosphati-
dylinositol-3,4,5-trisphosphate 
binding. 
Nervous system development; 
positive regulation of long-term 
synaptic potentiatio ; postsynap-
ic modulation of chemical synap-
tic transm ssion; signal transduc-






Transcriptional activator; plays a 
role in brain developme  being 
required for the specification and 
the proliferation of the interme-
diate progenitor cells and their 
progeny in the cerebral cortex. 
Adaptiv  immun  response; brain 
development; cell fate specifica-
tion; cerebral cortex neur  differ-
entia ion; cerebral cortex regionali-






P obably transpor s th roxi e 
from the bloodstream to the 
brain; hormone activity; identical 
protein binding; protein-contain-
ing complex bin ing; thyroid 
hormone binding. 
C llular prot in met b lic rocess; 
extracellular matrix organization; 
neutrophil degranulation; purine 
nucleobase met bolic process. 
1 Disease-specific, brain region non-exclusive differentially expressed genes (DEGs). 2 Disease-specific, brain region exclu-
sive DEGs. 3 Disease non-specific, brain region exclusive DEGs. 4 Information gathered from http://uniprot.org. * Gene, the 
expression of which is highly differential also between the sub-clusters of the given sCJD brain region. † Gene, the expres-
sion of which is highly differential also between the sub-clusters of the sCJD cerebellum, but not frontal cortex samples. 
2.3. Inter-Regionally Overlapping Canonical Pathways nd Upstream Regulators 
Within the FC samples, 184 genes were identified as differentially expressed between 
the sCJD and control tissues (Supplementary material S1b, a list of the 184 DEGs); 
whereas, within the CB samples, we identified 88 DEGs (Supplementary material S1c, a 
Terminates the action of






































binding; identical protein bind-
ing; protein omodimerization 
activity; tau protein binding. 
Astrocyte differentiation; central 
nervous system development; in-
nate immune response; regulation 
of cell shape; positive regulation of 
cell population proliferation and 
apoptotic process. 
SL 6A1,  
Solute Carrier 
Family 6 Mem-
ber 1  
Terminates the action of GABA 
by its high affinity sodium-de-
pendent reuptake into presynap-
tic terminals; identical pr tein 
binding; metal ion binding; neu-
rotra smi ter binding. 
Neurotransmitter transport; neu-
rotransmitter reuptake; synapse 














and SOCS Box 
Containing 2  
Mediates he ubiquitinati n and 
sub equent proteasomal degra-
dation of target proteins. 





Homeobox 1  
Transcriptional activator or re-
pressor; plays a role in differenti-
ation of interneurons, in the de-
velopment of the ventral fore-
brain and diencephalic subdivi-
sions, in craniofacial patterning 
and morphogenesis. 






Acts as a messenger during syn-
aptic development and remodel-
ing; calmodulin binding; phos-
ph tidic acid binding; phosphati-
dylinositol-3,4,5-trisphosphate 
bind ng. 
Nervous system development; 
positive regulation of long-term 
synaptic potentiation; postsynap-
tic modulation of chemical synap-
tic transmission; signal transduc-






Transcriptional activator; plays a 
role in brain development being 
required for the specification and 
the pro ife tion of the interme-
diate progenitor c lls and their 
p geny in the ce ebral c rtex. 
Adaptive immune response; brain 
development; cell fate specifica-
tion; cerebral cortex neuron differ-
entiation; cerebral cortex regionali-






Probably transports thyroxine 
from the bloodstream to the 
brain; hormone activity; identical 
protein binding; protein-contain-
ing complex binding; t yroid 
hormone binding. 
Cellular protein metabolic process; 
extracellular matrix organization; 
neutrophil degranulation; purine 
nucleobase metabolic process. 
1 Disease-specific, brain region non-exclusive differentially expressed genes (DEGs). 2 Disease-specific, brain region exclu-
sive DEGs. 3 Disease non-specific, brain region exclusive DEGs. 4 Inf rm tion gathered from h tp://uniprot.org. * Gene, the 
expression of which is highly differential also between the sub-clusters of the given sCJD brain region. † Gene, the expres-
sion of which is highly differential also between the sub-clusters of the sCJD cerebellum, but not frontal cortex samples. 
2.3. Inter-Regionally Overlapping Canonical Pathways and Upstream Regulators 
Within the FC samples, 184 genes were identified as differentially expressed between 
the sCJD and control tissues (Supplementary material S1b, a list of the 184 DEGs); 































bind ng; identical protein bind-
ing; protein homodimerization 
activi ; ta  rot i  binding. 
Astrocyte differentiation; central 
nervous system de lopment; i -
nate immune resp nse; regulation 
of cell sha e; posi ive regulation of 
cell population prolif ration and 
apoptotic process. 
SLC A1,  
Solute Carrier 
Family 6 Mem-
ber 1  
T rmi ates the act o  of GABA 
by its high affinity sodium-de-
pe ent reuptake into presynap-
tic terminals; identical protein 
binding; metal ion binding; neu-
rotransmitter binding. 
Neurotransmitter transpo t; neu-
r transmitter reuptake; synapse 














and SOCS Box 
Con ining 2  
Mediates the ubiquiti ation and 
subsequent proteasomal degra-
dation of target proteins. 





Homeobox 1  
Tr scriptional activator or re-
pres or; pl ys a rol  in di ferenti-
tio of inter eurons, in the de
velopment of the ventral fore-
brain and dienc phalic subdivi-
sions, in craniofacial patterning 
nd morph genes s. 






Acts  a messenger during syn-
aptic evelopment and remodel-
ing; calmodulin binding; phos-
phat dic acid binding; phosphati-
dylinositol-3,4,5-trisphosphate 
binding. 
Nervous sy tem development; 
p sitive regulati  of long-term 
synaptic potentiatio ; postsynap-
c m dulation of chemical synap-
c transm ssion; sig al tra sduc-






Transc iptional activator; plays a 
role in brain developme t b ing 
required for the specification and 
the proliferation of the interme-
diate progenitor cells and their 
progeny in the cerebral cortex. 
Adaptiv  immun  response; brain 
development; cel fate specif ca-
tion; cerebral cortex neur differ-
ent a ion; cerebral cortex regionali-
zation; stem cell populat on 




P obably transpor s th roxi e 
fro  th  loodstream to the 
brain; hormone activi y; identical 
protein binding; protein-contain-
ing complex bin ing; thyroid 
hormone binding. 
Cellular protein met b lic rocess; 
extracellular matrix organization; 
neutrophil degranulation; purine 
nucleobase met bolic process. 
1 Disease-specific, brain region non-exclusive differentially expressed genes (DEGs). 2 Disease-specific, brain region exclu-
sive DEGs. 3 Disease non-specific, brain region exclusive DEGs. 4 Information gathered from http://uniprot.org. * Gene, the 
expression of which is highly differential also between the sub-clusters of the given sCJD brain region. † Gene, the expres-
sion of which is highly differential also between the sub-clusters of the sCJD cerebellum, but not frontal cortex samples. 
2.3. Inter-Regionally Overlapping Canonical Pathways and Upstream Regulators 
Within t e FC samples, 184 gen s were identified as differentially expressed between 
the sCJD and control tissues (Supplementary material S1b, a list of the 184 DEGs); 
whereas, within the CB samples, we identified 88 DEGs (Supplementary material S1c, a 
Transc i ti al activator
or repressor; plays a role
in differe tiati n of
interneurons, in the
development of the




































binding; identical protein bind-
ing; protein homodimerization 
activi y; tau protein bindi g. 
Astrocyte differentiation; central 
nervous system development; in-
nate immune response; regulation 
of cell shape; positive regulation of 





ber 1  
Terminates the action of GABA 
by its high affinity sodium-de-
pendent reuptake into presynap-
tic terminals; identical pr tein 
binding; metal ion binding; neu-
rotra smitter binding. 
Neurotransmitter transport; neu-
rotransmitter reuptake; synapse 
organization; transport across 













and SOCS Box 
Containing 2  
Mediates the ubiquitinati n and 
sub equent proteasomal degra-
dation of target proteins. 





Homeobox 1  
Transcriptional activator or re-
pr ssor; plays a role in different -
ation of interneurons, in the de-
velopment of the ventral fore-
brain and diencephalic subdivi-
sions, in craniofacial patterning 
and morphogenesis. 






Acts as a messenger during syn-
aptic development and remodel-
ing; calmodulin binding; phos-
ph tidic acid binding; phosphati-
dylinositol-3,4,5-tris hosphate 
binding. 
Nervous system development; 
positive regulation of long-term 
synaptic potentiation; postsynap-
tic modulation of chemical synap-
tic transmission; signal transduc-






Transcriptional activator; plays a 
role in brain development being 
required for the specification and 
the prolife tion of the interme-
diate progenitor c lls and their 
p geny in the ce ebral c rtex. 
Adaptive immune response; brain 
development; cell fate specifica-
tion; cerebral cortex neuron differ-
entiation; cerebral cortex regionali-






Probably transports thyroxine 
from the bloodstream to the 
brain; hormone activi y; identical 
protein binding; protein-contain-
ing complex binding; t yroid 
hormone binding. 
Cellular protein metabolic process; 
ext cellular matrix organization; 
neutrophil degranulation; purine 
nucleobase metabolic process. 
1 Dis a e-specific, brain region non- xclusive differentially expressed genes (DEGs). 2 Disease-sp cific, brain region exclu-
ive DEGs. 3 Di ease non-specific, brain region exclusive DEGs. 4 Inf rmatio  gathered from http://uniprot.org. * Gene, the 
expression of which is highly diff rential also between the sub-clusters of the given sCJD brain region. † Gene, the expres-
sion of which is highly differential also between the sub-clusters of the sCJD cerebellum, but not frontal cortex samples. 
2.3. Inter-Regionally Overlapping Canonical Pathways nd Upstream Regulators 
Within the FC samples, 184 genes were identified as differentially expressed between 
the sCJD and control tissues (Supplementary material S1b, a list of the 184 DEGs); 
whereas, within the CB samples, we identified 88 DEGs (Supplementary material S1c, a 











regulation of lo g-ter
synaptic p tentiation;
ost ynaptic modulation
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binding; identical protein bind-
ing; protein homodimerization 
activity; tau protein binding. 
Astrocyte differentiation; central 
nervous system development; in-
nate immune response; regulation 
of cell shape; positive regulation of 





ber 1  
Terminates the action of GABA 
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2.3. Inter-Regionally Overlapping Canonical Pathways and Upstream Regulators
Within the FC samples, 184 genes were identified as differentially expressed between
the sCJD and control tissues (Supplementary material S1b, a list of the 184 DEGs); whereas,
within the CB samples, we identified 88 DEGs (Supplementary material S1c, a list of the
88 DEGs). In total, 68 DEGs were found to be common between FC and CB (Figure 4a;
Supplementary material S1d, a list of 68 DEGs).
Interestingly, despite differences in the number of DEGs identified in the FC and
CB sCJD disease signature, the effects of these gene sets appear very similar at the path-
way level; a near-complete overlap between canonical pathways for the two contrasts
(FC sCJD and CB sCJD) is observed, with the main difference being in the p-values, which
reflect higher significance for FC due to the higher number of DEGs identified in this
tissue. The most significantly enriched canonical pathways shared between FC and CB
included the neuroinflammation signaling pathway, dendritic cell maturation, NF-κB sig-
naling, acute phase response signaling, and Myc-mediated apoptosis signaling (Figure 2).
An overlap was also observed among upstream regulators identified in the FC and CB
sCJD samples when compared to the control samples. The top inter-regionally common
upstream regulators included IFNG, TNF, TGFB1, IL-6, and IL-1B (Figure 3). Lists of the
top 40 identified pathways and upstream regulators are provided in Figures 2 and 3.
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2.4. sCJD FC and CB-Exclusive DEGs
Although the FC and CB sCJD signatures shared 68 DEGs, resulting in largely over-
lapping core molecular processes, each brain region also demonstrated unique single-gene
expression patterns. The FC-exclusive-sCJD signature consisted of 116 DEGs, while the
CB-exclusive-sCJD signature consisted of only 20 DEGs (Figure 4a; Supplementary material
S1e, lists of 116 and 20 DEGs). When the FC-exclusive-sCJD signature was applied to the
CB samples, the sCJD and control tissue clusters were formed, confirming that the FC 116
DEGs are sCJD-specific and that their expression profile differs between the two brain
regions (Figure 4b,c).
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Although the sCJD CB-exclusive signature consisted of only 20 DEGs, they clearly
clustered the sCJD and control tissue CB samples apart. Interestingly, when the CB signa-
ture was tested on the FC samples, the clustering of the sCJD and control tissue samples
was rather poor, confirming that this 20 DEG profile is sCJD CB-specific (Figure 4d,e).
However, when evaluating these results, one should keep in mind that the analy-
sis is based on and biased by a background of 800 pre-selected genes that are mainly
neuroinflammatory.
2.5. Sub-Regional Differences: Variance in the Strength of Neuroinflammation
Interestingly, under the sCJD clusters there was a formation of two FC and two CB
sub-clusters (Figure 1a). In FC, the gene expression analysis of the first sub-cluster (C1)
versus the second sub-cluster (C2) revealed 181 DEGs which overlapped with the FC
sCJD versus control tissue DEG signature (Figure 5a) (Supplementary material S1f, a list
of the 181 DEGs). In CB, the difference in gene expression pattern between the two sub-
clusters was even more apparent because the C2 resembled the gene expression pattern
seen in the control tissues, which suggested that some sCJD patients may present with
pronounced cerebellar inflammation and some seem to lack neuroinflammatory changes
(Figure 1a). The gene expression analysis of the CB C1 versus C2 revealed 50 DEGs (Figure
5b; Supplementary material S1g, a list of the 50 DEGs).
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Altogether, analyses of the DEGs involved in the FC and CB sub-clusters formation
confirmed variance in the intensity of sub-regional inflammation and the existence of
“strong” and “weak” neuroinflammation profiles.
3. Discussion
The involvement and dysregulation of major biological processes such as immune
system response, metabolism, developmental biology, and vesicle-mediated transport
in prion disease pathogenesis have been confirmed by numerous transcriptomic studies
using both human and animal tissues [14–16,18,19,24–26,28–31]. However, data on the
neuroinflammatory events taking place in different brain regions of human sCJD are
surprisingly scarce.
Thus, we hypothesized that the expression of neuroinflammation-associated genes
is different in distinct brain regions and aimed to identify disease- and brain region-
specific genes as well as to provide an overview of the neuroinflammatory landscape in
sCJD patients’ brains using an 800 gene expression panel designed by NanoString. To our
knowledge, this is the first published study describing the expression of neuroinflammation-
associated genes in human brain samples from the FC and CB of sCJD patients and age-
and sex-matched normal controls using such a panel.
We generated data that provide an overview of differentially expressed genes, the
most involved canonical pathways and upstream regulators, and their biological functions
in sCJD patients as compared to controls; in FC compared to CB; and even the sub-clusters
observed within each brain region. The data indicated neuroinflammatory differences in
distinct brain regions and varying intensities of inflammation within the same brain regions
of sCJD patients with different disease subtypes, which broadens our understanding of
prion disease pathogenesis from the aspect of inflammation (Table 1).
Interestingly, the regional sub-clusters could not be explained by patients’ sex, age
group, polymorphic codon 129 in the PRNP, or type of dominant PrPSc. Undoubtedly, a
study with a larger number of sCJD cases with different subtypes would ensure firmer
conclusions. Nevertheless, the current results imply that the impact of the sCJD subtype
may not be the strongest or sole factor determining the strength of the neuroinflammatory
gene expression profile.
Curiously, a study by Makarava et al. performed with the NanoString neuroinflam-
mation panel to investigate mice infected with 22L (astrocyte-associated) and ME7 (neuron-
associated) PrPSc strains found that their established signature for prion disease-associated
gene expression was independent of the brain region or prion cell tropism [32].
In our study, however, although the neuroinflammation may seem uniform, consider-
ing the overlap of canonical pathways and upstream regulators, we still see specific genes,
the expression of which is regulated differently in different brain regions. It is important to
look for changes at the single gene expression level to ensure that their unique and subtle
roles in disease pathogenesis are not overlooked when multiple genes are pooled together
in the enriched sets needed for pathway determination.
Other independent research groups using PCR and immunohistochemistry-based gene
and protein expression approaches for the investigation of human sCJD brain immunity
also identified the presence of regional differences.
For example, Llorens et al. investigated the expression of 25 selected inflammation-
associated genes in the FC and CB of 30 sCJD patients with the MM 1 and VV 2 subtypes [25].
They observed that the upregulation of these genes was higher in the FC in sCJD MM 1 and
in the CB in sCJD VV 2 and concluded that regional gene regulation differences depend
on the patient’s genotype at codon 129 in the PRNP [25,26]. Furthermore, Franceschini
et al. proposed that the PrPSc strain and polymorphic codon 129 also influence regional
microglia activation, because their study of activated microglia distribution throughout
the brain of different sCJD subtypes demonstrated that microgliosis, PrPSc deposition, and
spongiform change were correlated but varied markedly among the sCJD subtypes [11].
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Importantly, the studies on human sCJD samples were in agreement with the notion
that neuroinflammation in the brain of sCJD patients is not regionally uniform. However,
to understand the key cellular and molecular differences between and within distinct brain
regions presenting variable pathology, a larger and statistically higher-powered study
is needed, preferably combining data on spatial cells’ distribution and their molecular
signatures.
Currently, scientific evidence implies that microglia are the key drivers of neuroin-
flammation in prion disease, and the pathway analysis based on the DEG sets we identified
in our study supports this notion, as the most significantly involved pathways include
neuroinflammation signaling and metabolic processes [19]. Nevertheless, our pathway
analysis also suggests the importance of brain dendritic cells, providing new insight on the
different cell types involved in the disease development (Figure 2).
Furthermore, in our study we identified regionally exclusive genes that are likely
involved in the formation and development of different brain structures, such as FC and CB.
However, we also provided a list of disease-associated top differentially expressed genes
in the two brain regions as well as common DEGs. A few literature sources attempting to
explain the role of these genes in prion or other neurodegenerative disease pathogenesis
were found.
For example, in the brain SERPINA3 is mainly expressed by astrocytes, and its deregu-
lation has been linked to the pathogenesis of several diseases, including schizophrenia and
Alzheimer’s [33–35]. SERPINA3 overexpression has previously been reported in the frontal
and occipital cortices of various human prion diseases [36]. Several hypotheses considering
the pathogenic effects of SERPINA3 overexpression in prion diseases have been proposed—
e.g., that it may contribute to PrPSc formation or hamper PrPSc clearance [36]. However,
conclusive explanations for the molecular mechanism of SERPINA3 upregulation and its
role in disease development are still lacking.
SOCS3 proteins are expressed by multiple immune cells where they reside in a cell’s cy-
tosol and negatively regulate cytokines that signal through the JAK/STAT pathway. SOCS3
was one of the few identified genes that were suggested to be prion disease pathogenesis-
specific [37]. In another RNA expression study with prion-infected mice models, SOCS3
was detectable early and regulated by the phosphorylation of specific STAT protein com-
plexes [38].
FCER1G is a microglia-expressed hub gene associated with aging and neurodegener-
ation [39]. Changes in the FCER1G expression were also reported in mice infected with
PrPSc [40,41]. The FCER1G is a part of larger molecular complexes and among its other
functions is considered to selectively mediate IL-4 production by basophils, to prime T
cells towards effector T-helper 2 subset, to form a functional signaling complex in myeloid
cells, and to drive the maturation of antigen-presenting cells.
CD44 expression is linked to reactive astrocyte heterogeneity observed in the brain
during prion disease in mice, and it was suggested as a biomarker to enhance the iden-
tification of distinct prion agent strains [42]. CD44 antigen is a receptor for hyaluronic
acid and can interact with SPP1 and other ligands, allowing it to participate in a wide
variety of cellular functions, including lymphocyte activation, recirculation and homing,
hematopoiesis, and tumor metastasis.
Finally, the SPP1 encodes a cytokine known for the upregulation of interferon-gamma
and interleukin-12 expression and the reduction in interleukin-10 production, leading
to type I immunity characterized by intense phagocytic activity. SPP1 is a key factor
regulating the degeneration and regeneration of injured nerves via the c-Fos, PKCα, and
p-ERK/ERK pathways [43]. Moreover, SPP1 was found to be upregulated and act as
an essential modulator of macrophage phenotypes and their ability to clear pathogenic
beta-amyloid forms in mice models of Alzheimer’s disease [44,45]. However, its role in
prion diseases has not yet been determined.
The biological roles of these and other genes listed in Table 1 seem highly relevant to
prion disease pathogenesis and suggest the importance of various brain cells’ proliferation,
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differentiation, migration, and trafficking characteristics. To elucidate the phenotypic
and functional heterogeneity of brain cells in their various pathologic microenvironments
observed in distinct brain regions as well as within the same brain region of different
human sCJD sub-types, methods that enable the collection of multiplex molecular and
spatial information, such as NanoString GeoMx digital spatial profiler or advanced mass
spectrometry-based proteomics, could be of great value [46,47]. For the reproduction and
research of specific brain microenvironments and cell subtypes within them as well as the
investigation of the effectiveness of novel therapeutic compounds for disease treatment or
prevention, humanized cerebral organoid platforms and advanced spatial transcriptomic
techniques such as multiplexed error-robust fluorescence in situ hybridization could also
benefit the future research of prion disease [48,49].
4. Materials and Methods
4.1. Samples
Fresh frozen (FF) brain samples from two brain regions—namely, the FC and CB—
were collected from 14 sCJD patients and 10 brain donors with no neuropathological
changes. In total, 47 RNA samples were analyzed: 27 sCJDs and 20 normal controls. One
commercial brain RNA sample included in the NanoString nCounter training kit (Lot.
5201A-0618, 80036) was used as a control and a reference sample for potential experiments
in the future.
Age- and sex-matched sCJD and healthy brain samples included seven male and
female sCJD patients and five male and female healthy brain donors. Median age at death
of sCJD patients was 73 years (range 60–77), and the median age at death of the healthy
brain donors was 67.5 years (range 57–74). A maximum of 3 years difference was allowed
when selecting age- and sex-matched healthy brain donors for sCJD patients.
The included patients had the following sCJD subtypes: 5/14 were sCJD MM 1, 4/14
were VV 2, and 5/14 were single cases of different subtypes, including MV 1, MV 2K, MV
2K + C, MM 1 + 2, and MM 2C + 1.
All the sCJD samples were from the Danish prion diseases cohort gathered at the
Danish Reference Center for Prion Diseases. All the control tissue samples were received
from Edinburgh Brain Bank, University of Edinburgh, Scotland (Supplementary material
S3).
4.2. RNA Extraction and Evaluation
Total RNA extraction from FF brain samples was performed using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) following the manufacturer’s recommendations. The Bioana-
lyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) and NanoDrop spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA) were used to evaluate the extracted RNA
purity (wavelength absorbance ratio A260/280 ~2.0, and A260/230 ~2.0), concentration
(ng/µL), and quality (DV300 ≥ 50%, the percentage of RNA fragments ≥300 nucleotides)
or integrity (RIN > 4).
4.3. NanoString
A commercially available NanoString 757 gene neuroinflammation panel comple-
mented with an additional 30 genes of choice and 13 housekeeping genes was used to
generate the expression data (Supplementary material S2, a list of genes in the panel).
To our knowledge, this new panel with pre-selected genes associated with immunity
and inflammation, neurobiology and neuropathology, and metabolism and stress has not
previously been used in investigations of human prion diseases.
The total RNA input for each sample extracted from fresh frozen tissues was 50 ng.
All the included samples had an A260/280 absorbance ratio between 1.97 and 2.17, and
at least 50% of all the RNAs present in each sample were equal to or longer than 300 base
pairs; alternatively, the RNA integrity value (RIN) value had to exceed 4.
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The nCounter XT CodeSet Gene Expression Panel assay and Prep Station were used
for the direct hybridization of unique barcodes to target RNAs and their placement into
the cartridges. A Digital Analyzer was used for the detection and the counting of hy-
bridized probes, and nSolver software version 4.0 was used for data normalization. All the
procedures were performed following the NanoString guidelines.
Using nSolver Advanced Analysis, the quality of the experiment was assessed by
hybridization effectiveness, which is measured by the expression of internal six positive
and eight negative RNA control transcripts included in the CodeSet. The same six positive
controls were used for the normalization of the run-to-run introduced count variability.
The sample-to-sample variability was normalized using housekeeping genes selected
by the geNorm algorithm. In total, 13 housekeeping genes were included in the neuroin-
flammation panel: AARS, ASB7, CCDC127, CNOT10, CSNK2A2, FAM104A, GUSB, LARS,
MTO1, SUPT7L, TADA2B, TBP, XPNPEP1.
4.4. Statistical Analysis
The genes that were differentially expressed between groups were identified by
ANOVA (p < 0.05), and significance was adjusted for multiple testing by estimating false
discovery rate (FDR) [50]. For a gene to be considered differentially expressed in a paired
analysis, the p value should be lower than 0.05 (p < 0.05) and its log2-fold change higher
than 1 (log2FC > 1), unless indicated otherwise. All the data were log2-transformed prior
to analysis and visualization in Qlucore Omics Explorer v.3.6 (Qlucore AB, Lund, Sweden),
including principal component analysis, heat maps, and unsupervised hierarchical cluster-
ing. Functional analysis, including pathway, upstream regulator, and network analysis,
was performed in Ingenuity Pathway Analysis (IPA, Qiagen, Redwood City, CA, USA).
5. Conclusions
The current study presents the results of the first attempt to reveal molecular neu-
roinflammatory events occurring in different brain regions of sCJD patients using the
NanoString 800 gene neuroinflammation panel+. Our preliminary data on regional brain
microenvironments indicate distinct neuroinflammation patterns between the different
brain regions and within the same brain region, implying the presence of immune cells
with different activation statuses and molecular profiles that might be specific to certain
co-factors in their immediate microenvironment.
The current study presents an overview of the most involved neuroinflammation-
associated pathways and their biological functions affecting different brain regions in sCJD.
Furthermore, we identified several significantly deregulated and functionally interesting
genes that are of value for further studies.
Future research is needed for an extensive molecular characterization of different
cell types in order to recognize their impact on the microenvironment and, hence, disease
development. This knowledge is needed to improve the current diagnostic strategies and
speed up the discovery of therapeutically targetable molecules.
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